[Shu Taishen: first patient Administration of Phase Ib/II Clinical trial of STSG-0002 injection completed] May 11, Shu Taishen announced that recently, the STSG-0002 injection developed by the company and its wholly-owned subsidiary Sannojiayi completed the first patient administration of phase Ib/II clinical trial for indications of chronic hepatitis B in the first Hospital of Peking University.